Content of resolutions adopted by the Annual General Meeting on June 26, 2025, appointment of a member of the Company's Supervisory Board

Current Report No. 27/2025

Date of preparation: June 26, 2025

Subject: Contents of resolutions adopted by the Annual General Meeting on June 26, 2025, appointment of a member of the Company's Supervisory Board

Legal basis: Article 56 (1) (2) of the Act on Offering - current and periodic information

The Management Board of Captor Therapeutics S.A., based in Wrocław, Poland (the "Company"), hereby provides the contents of the resolutions adopted by the Annual General Meeting of the Company on June 26, 2025 (the "AGM").

The AGM did not waive consideration of any of the items on the planned agenda. There were no objections to the adopted resolutions.

Under the adopted resolutions, the AGM appointed Mr. Andrew Galazka to the Company's Supervisory Board.

The Company attaches a resume of Mr. Andrew Galazka describing his previous positions and career.

Mr. Andrew Galazka submitted a statement (attached), confirming that he does not conduct activities competitive to those conducted by the Company, and does not participate in a competitive company/partnership as a partner in a civil partnership, commercial partnership or company, as well as does not participate in a competitive legal person as a member of its body. Mr. Andrew Galazka, according to the statement, is not registered in the Register of Insolvent Debtors maintained under the National Court Register Act.

Detailed legal basis:

§ 5 (5) and § 19(1)(6) of the Regulation of the Minister of Finance of 29 March 2018 on current and periodic information provided by issuers of securities and conditions for recognizing as equivalent information required by the laws of a non-member state.